Published in Women's Health Weekly, December 1st, 2005
Study 1: Risedronate proves to be effective as an anti-osteoporotic treatment in women with IBD in remission.
Recent research published in the journal Osteoporosis International revealed that patients "With inflammatory bowel disease (IBD) have frequently a bone mineral density (BMD) significantly lower than age-matched healthy subjects. The low BMD observed in IBD patients is related also to a higher incidence of bone fractures."
S. Palomba and colleagues performed a "prospective randomized study to evaluate the effect of 1-year risedronate...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.